Literature DB >> 11517968

Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression.

G Nagashima1, J Asai, R Suzuki, T Fujimoto.   

Abstract

We investigated the expression of transforming growth factors (TGFs), platelet-derived growth factor (PDGF), progesterone receptor (PgR), and c-myc in 20 cases of meningioma of various grades: 17 benign, 2 atypical, and 1 anaplastic. All cases of atypical and anaplastic meningioma were positive for c-myc, whereas all 17 benign meningiomas were negative for c-myc immunostaining. Expression of TGF-alpha, TGF-beta, and PDGF-BB proteins was seen in more than 80% of the meningioma cases and was not restricted to their histological grade of meningioma. PgR was expressed mainly in benign meningiomas. Moreover, the cells expressing c-myc protein were not usually stained by MIB-1. These results indicate that c-myc does not directly work on the proliferation of meningioma cells, and even in homogeneous meningioma cells, there may be many functional variations that lead the meningioma cells to their growth.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517968     DOI: 10.1007/BF02478918

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  12 in total

1.  Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.

Authors:  David A Reardon; Andrew D Norden; Annick Desjardins; James J Vredenburgh; James E Herndon; April Coan; John H Sampson; Sridharan Gururangan; Katherine B Peters; Roger E McLendon; Julie A Norfleet; Eric S Lipp; Jan Drappatz; Patrick Y Wen; Henry S Friedman
Journal:  J Neurooncol       Date:  2011-09-22       Impact factor: 4.130

Review 2.  Advances in meningioma genetics: novel therapeutic opportunities.

Authors:  Matthias Preusser; Priscilla K Brastianos; Christian Mawrin
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

3.  A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.

Authors:  Jeffrey J Raizer; Sean A Grimm; Alfred Rademaker; James P Chandler; Kenji Muro; Irene Helenowski; Laurie Rice; Katie McCarthy; Sandra K Johnston; Maciej M Mrugala; Marc Chamberlain
Journal:  J Neurooncol       Date:  2014-01-22       Impact factor: 4.130

Review 4.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

5.  Disruption of Smad4 in mouse epidermis leads to depletion of follicle stem cells.

Authors:  Leilei Yang; Lijuan Wang; Xiao Yang
Journal:  Mol Biol Cell       Date:  2008-12-10       Impact factor: 4.138

6.  Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Andrew D Norden; Timothy F Cloughesy; Lauren E Abrey; Howard A Fine; Susan M Chang; H Ian Robins; Karen Fink; Lisa M Deangelis; Minesh Mehta; Emmanuelle Di Tomaso; Jan Drappatz; Santosh Kesari; Keith L Ligon; Ken Aldape; Rakesh K Jain; Charles D Stiles; Merrill J Egorin; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

7.  Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.

Authors:  Thomas J Kaley; Patrick Wen; David Schiff; Keith Ligon; Sam Haidar; Sasan Karimi; Andrew B Lassman; Craig P Nolan; Lisa M DeAngelis; Igor Gavrilovic; Andrew Norden; Jan Drappatz; Eudocia Quant Lee; Benjamin Purow; Scott R Plotkin; Tracy Batchelor; Lauren E Abrey; Antonio Omuro
Journal:  Neuro Oncol       Date:  2014-08-06       Impact factor: 12.300

8.  Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.

Authors:  Yiping Shen; Fabio Nunes; Anat Stemmer-Rachamimov; Marianne James; Gayatry Mohapatra; Scott Plotkin; Rebecca A Betensky; David A Engler; Jennifer Roy; Vijaya Ramesh; James F Gusella
Journal:  BMC Med Genomics       Date:  2009-07-09       Impact factor: 3.063

9.  Expression of merlin, NDRG2, ERBB2, and c-MYC in meningiomas: relationship with tumor grade and recurrence.

Authors:  B R Ongaratti; C B O Silva; G Trott; T Haag; C G S Leães; N P Ferreira; M C Oliveira; J F S Pereira-Lima
Journal:  Braz J Med Biol Res       Date:  2016-03-18       Impact factor: 2.590

Review 10.  Emerging Medical Treatments for Meningioma in the Molecular Era.

Authors:  Fares Nigim; Hiroaki Wakimoto; Ekkehard M Kasper; Linda Ackermans; Yasin Temel
Journal:  Biomedicines       Date:  2018-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.